A glycan-based plasmonic sensor for prostate cancer diagnosis

DC FieldValueLanguage
dc.contributor.authorLamarre, Mathieu-
dc.contributor.authorTremblay, Thomas-
dc.contributor.authorBansept, Marc-Antoine-
dc.contributor.authorRobitaille, Karine-
dc.contributor.authorFradet, Vincent-
dc.contributor.authorGiguère, Denis-
dc.contributor.authorBoudreau, Denis-
dc.date.accessioned2022-06-21T20:20:39Z-
dc.date.available2022-10-01T00:00:00Z-
dc.date.issued2021-10-01-
dc.identifier.issn0003-2654fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/73624-
dc.description.abstractProstate cancer affects thousands of men who undergo clinical screening tests every year. The main biomarker used for the diagnosis of prostate cancer, prostate specific antigen (PSA), presents limitations that justify investigating new biomarkers to improve reliability. Antibodies against the tumor-associated carbohydrate antigen (Tn), or TACA, develop early in carcinogenesis, making them an interesting alternative as a target for prostate cancer diagnostics. In this work, the Tn antigen was synthesized and immobilized on a surface plasmon resonance sensor coated with a polydopamine/polyethylene oxide mixed layer used both as an anchoring surface for Tn capture moieties and to minimize surface fouling. The sensor could be regenerated and reused at least 60 times without any significant loss in sensitivity. Anti-Tn antibodies were detected in the 0-10 nM concentration range with detection limits of 0.1 and 0.3 nM in spiked buffer solutions and diluted human blood serum samples, respectively. Finally, as a proof-of-concept, this carbohydrate-based sensor was used to successfully discriminate blood serum samples from prostate cancer-free and prostate cancer patients.fr
dc.languageengfr
dc.publisherRoyal Society of Chemistryfr
dc.titleA glycan-based plasmonic sensor for prostate cancer diagnosisfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationAnalyst, Vol. 146 (22), 6852-6860 (2021)fr
dc.identifier.doi10.1039/D1AN00789Kfr
dc.identifier.pubmed34623365fr
dc.subject.rvmProstate -- Cancer -- Diagnostic moléculairefr
dc.subject.rvmRésonance plasmonique de surfacefr
dc.subject.rvmAntigènes tumorauxfr
dc.subject.rvmImagerie pour le diagnostic -- Techniques numériquesfr
rioxxterms.versionAccepted Manuscriptfr
rioxxterms.version_of_recordhttps://doi.org/10.1039/D1AN00789Kfr
bul.rights.periodeEmbargo12 moisfr
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
Description SizeFormat 
Lamarre et al, Analyst (manuscript).docx
1.68 MBMicrosoft Word XML    Request a copy
Lamarre et al, Analyst (SI) 5-4-2021.docx
2.09 MBMicrosoft Word XML    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.